121 related articles for article (PubMed ID: 38546663)
41. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
[TBL] [Abstract][Full Text] [Related]
42. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
[No Abstract] [Full Text] [Related]
43. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
44. The Correlative Strength of Objective Physical Assessment Against the ECOG Performance Status Assessment in Individuals Diagnosed With Cancer.
Quinn SE; Crandell CE; Blake ME; Bontrager AM; Dempsey AG; Lewis DJ; Hamm JT; Flynn JM; Smith GS; Wingard CJ
Phys Ther; 2020 Mar; 100(3):416-428. PubMed ID: 32043132
[TBL] [Abstract][Full Text] [Related]
45. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status.
Fiorin de Vasconcellos V; Rcc Bonadio R; Avanço G; Negrão MV; Pimenta Riechelmann R
BMC Palliat Care; 2019 May; 18(1):42. PubMed ID: 31109330
[TBL] [Abstract][Full Text] [Related]
46. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
[TBL] [Abstract][Full Text] [Related]
47. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
Agarwal M; Liu A; Almquist D; Langlais BT; Leventakos K; Yu NY; Manochakian R; Ernani V
Cancer; 2023 Nov; 129(22):3546-3553. PubMed ID: 37548029
[TBL] [Abstract][Full Text] [Related]
48. Remote Monitoring of the Performance Status and Burden of Symptoms of Patients With Gastrointestinal Cancer Via a Consumer-Based Activity Tracker: Quantitative Cohort Study.
Ghods A; Shahrokni A; Ghasemzadeh H; Cook D
JMIR Cancer; 2021 Nov; 7(4):e22931. PubMed ID: 34842527
[TBL] [Abstract][Full Text] [Related]
49. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study.
Agemi Y; Shimokawa T; Sasaki J; Miyazaki K; Misumi Y; Sato A; Aida S; Ishii M; Nakamura Y; Naoki K; Okamoto H
PLoS One; 2019; 14(1):e0210499. PubMed ID: 30653558
[TBL] [Abstract][Full Text] [Related]
50. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Sweeney CJ; Zhu J; Sandler AB; Schiller J; Belani CP; Langer C; Krook J; Harrington D; Johnson DH
Cancer; 2001 Nov; 92(10):2639-47. PubMed ID: 11745199
[TBL] [Abstract][Full Text] [Related]
51. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
[TBL] [Abstract][Full Text] [Related]
52. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
[TBL] [Abstract][Full Text] [Related]
53. Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan.
Murakawa Y; Sakayori M; Otsuka K
BMC Palliat Care; 2019 Jun; 18(1):45. PubMed ID: 31159782
[TBL] [Abstract][Full Text] [Related]
54. Exploring physical activity level in patients with thoracic cancer: implications for use as an outcome measure.
Maddocks M; Wilcock A
Support Care Cancer; 2012 May; 20(5):1113-6. PubMed ID: 22311375
[TBL] [Abstract][Full Text] [Related]
55. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis.
Assayag J; Kim C; Chu H; Webster J
Front Oncol; 2023; 13():1194718. PubMed ID: 38162494
[TBL] [Abstract][Full Text] [Related]
56. Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients.
Gresham G; Hendifar AE; Spiegel B; Neeman E; Tuli R; Rimel BJ; Figlin RA; Meinert CL; Piantadosi S; Shinde AM
NPJ Digit Med; 2018; 1():27. PubMed ID: 31304309
[TBL] [Abstract][Full Text] [Related]
57. Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer.
Rocha BMM; Dolan RD; Paiva CE; McGovern J; Paiva BSR; Preto DD; McMillan DC; Maia YCP; Laird BJ
J Pain Symptom Manage; 2023 Apr; 65(4):348-357. PubMed ID: 36493981
[TBL] [Abstract][Full Text] [Related]
58. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
Steffen McLouth LE; Lycan TW; Levine BJ; Gabbard J; Ruiz J; Farris M; Grant SC; Pajewski NM; Weaver KE; Petty WJ
Clin Lung Cancer; 2020 May; 21(3):255-263.e4. PubMed ID: 31917067
[TBL] [Abstract][Full Text] [Related]
59. Is the ECOG-PS similar to the sarcopenia status for predicting mortality in older adults with cancer? A prospective cohort study.
Sousa IM; Fayh APT
Support Care Cancer; 2023 Jun; 31(6):370. PubMed ID: 37266669
[TBL] [Abstract][Full Text] [Related]
60. Nutrition-inflammation marker enhances prognostic value to ECOG performance status in overweight or obese patients with cancer.
Zhang X; Zhang Q; Tang M; Zhang KP; Zhang XW; Song MM; Ruan GT; Sun Q; Li W; Xu HX; Cong MH; Deng L; Shi HP
JPEN J Parenter Enteral Nutr; 2023 Jan; 47(1):109-119. PubMed ID: 35589385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
